Protein co-aggregates of dense core amyloid plaques and CSF differ in rapidly progressive Alzheimer’s disease and slower sporadic Alzheimer’s disease
Authors:
Open Access
- 27 May 2025
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 17 (1) , 1-14
Abstract
The rapidly progressive phenotype of Alzheimer’s disease (rpAD) remains a rare and less-studied entity. Therefore, the replication of key results from the rpAD brain and cerebrospinal fluid (CSF) is lacking. A label-free quantitative LC-MS/MS analysis of proteins co-aggregating with core-amyloid $$\beta$$ plaques in fresh frozen tissue (FFT) from medial temporal regions of rpAD ( $$n=8$$ ) neuropathologically characterized at the National Prion Disease Pathology Surveillance Center (NPDPSC), compared with microdissected amyloid plaques from formalin-fixed, paraffin-embedded (FFPE) tissue blocks from patients with rpAD ( $$n=22$$ ) previously published from the NPDPSC cohort, was performed. Matched rpAD CSF from the FFT cases were compared to a previously published proteomic evaluation of CSF in the AD subtype with rapid progression. A total of 1841 proteins were characterized in the FFT study, of which 463 were consistently identified in every rpAD patient analyzed. One thousand two hundred eighty-three proteins were shared between the FFT and the prior FFPE study. FFT offered a more comprehensive proteomic profile than the prior FFPE study and prominently included the immune system pathways. Thirty-five proteins were shared in the FFT brain tissue, matched CSF from the same subjects, in which biological processes related to immune response were again notable. These results were validated against prior published proteomic CSF AD data with a faster rate of progression to identify the top 5 potential protein biomarkers of rapid progression in AD CSF. These results support a distinct immune-related proteomic profile in both the brain and the CSF that can be explored as potential biomarkers in the future for the clinical diagnosis of rpAD.
Keywords
Funding Information
- National Institute on Aging (1P30 AG062428, 1P30 AG062428, 1P30 AG062428)
- Keep Memory Alive Foundation
- Iverson Family Endowed Fund for Alzheimer’s Disease research.
This publication has 74 references indexed in Scilit:
- Tau in Alzheimer Disease and Related TauopathiesCurrent Alzheimer Research, 2010
- Clinical Features of Rapidly Progressive Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2010
- Apolipoprotein D: An overview of its role in aging and age-related diseasesCell Cycle, 2010
- DNA double-strand break signaling and human disordersGenome Integrity, 2010
- Trajectories of cognitive decline in Alzheimer's diseaseInternational Psychogeriatrics, 2009
- Can CSF biomarkers or pre‐treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?International Journal of Geriatric Psychiatry, 2009
- In-gel digestion for mass spectrometric characterization of proteins and proteomesNature Protocols, 2006
- Efficacy of Rivastigmine in Alzheimer’s Disease Patients with Rapid Disease Progression: Results of a Meta-AnalysisDementia and Geriatric Cognitive Disorders, 2005
- Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basisNeurobiology of Aging, 2000
- Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer DiseaseJournal of Neuropathology & Experimental Neurology, 1997